Table 1.
Baseline Characteristics.
| Baseline Characteristics | Experimental group: Statin + STS (n = 35) | Control group: Statin (n = 35) |
|---|---|---|
| Demographics | ||
| Male, N(%) | 18 (51.4) | 20 (57.1) |
| Age, mean ± SD | 66 ± 7.28 | 67.47 ± 6.52 |
| Diagnosis | ||
| NSTEMI, N(%) | 3 (8.6) | 4 (11.4) |
| UA, N(%) | 32 (91.4) | 31 (88.6) |
| Number of diseased vessels, N(%) | ||
| One | 11 (31.4) | 8 (22.9) |
| Two | 6 (17.1) | 6 (17.1) |
| three | 4 (11.4) | 8 (22.9) |
| Cardiovascular risk factors, N(%) | ||
| Hypertension | 27 (77.1) | 33 (94.3) |
| Hyperlipidemia | 26 (74.3) | 30 (85.7) |
| Diabetes mellitus | 17 (48.6) | 13 (37.1) |
| Smoking history | 9 (25.7) | 8 (22.9) |
| BMI (mean ± SD, kg/m2) | 24.47 ± 2.89 | 24.86 ± 3.72 |
| TIMI risk score, N(%) | ||
| High risk (score 5–7) | 2 (2.9) | 3 (4.3) |
| Middle risk (score 3–4) | 21 (30.0) | 20 (28.6) |
| Low risk (score 0–2) | 12 (17.1) | 12 (17.1) |
| Medication, N(%) | ||
| Beta-blocker | 21 (60.0) | 24 (68.6) |
| ACEI | 9 (25.7) | 12 (34.3) |
| ARB | 10 (28.6) | 10 (28.6) |
| CCB | 17 (48.6) | 19 (54.3) |
| Aspirin | 34 (97.1) | 29 (82.9) |
| Clopidogrel | 17 (48.6) | 24 (68.6) |
| Blood lipid (mean ± SD, mmol/L) | ||
| TC | 4.39 ± 1.28 | 4.22 ± 1.29 |
| TG | 1.71 ± 0.80 | 1.95 ± 0.92 |
| LDL | 2.73 ± 0.99 | 2.66 ± 0.85 |
All comparisons between the groups were not significantly different (p > 0.05 for all). ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CCB, calcium channel blocker; IQR, interquartile range; LDL, low density lipoprotein; NSTEMI, non-ST segment elevation myocardial infarction; SD, standard deviation; TC, total cholesterol; TG, triglyceride; TIMI, Thrombolysis in Myocardial Infarction; UA, unstable angina.